Luna AI

Ask Luna AI about markets, a ticker or your clients without leaving this page.

Opening the research desk…

AstraZeneca PLC (AZN) stock price, chart and research

AstraZeneca PLC (AZN) last traded at $184.02 at the close on November 16, 2026, down $0.43 (0.23%) on the day.

About AstraZeneca PLC

Sector: Healthcare; industry: Drug Manufacturers - General; headquarters: United Kingdom; CEO: Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.; 96,100 employees; listed since 1993-05-12.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and…

Financials

Revenue over the last 12 months was $62.38 billion, net income $11.03 billion, a profit margin of 17.7%. Revenue grew 7.3% from a year earlier.

Institutional owners of AZN (13F)

Tracked managers holding AZN in 13F filings for the quarter ending 2026-09-30:

ETFs that hold AZN

Research AZN with LunaTerminal

Market data via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.

Welcome back

Sign in to your research desk.

or

New here?

Portfolio report

Create an agent

Never include secrets in agent instructions.